Company intelligence / Profile preview
Nexcella
Los Angeles, California, United Statesnexcella.com ↗
- Ownership
- Public · IMMX
- Development stage
- Phase 1
01
Overview
NXC-201, the lead CAR-T program targeting BCMA, has shown promising early clinical results. In heavily pretreated multiple myeloma patients in ongoing Phase 1 trials, it achieved an overall response rate of 85% and a complete response rate of 71%. In AL amyloidosis patients, initial data showed a 100% complete and organ response rate. The therapy is notable for its short median cytokine release syndrome duration (~2 days) and mild tolerability profile. No grade 3 or delayed neurotoxicity was observed in high-volume disease or AL amyloidosis cohorts. The product aims to be the first outpatient CAR-T due to its safety profile.
- Therapeutic areas
- OncologyImmunologyHematology
- Modalities
- Chimeric Antigen Receptor T cell therapy (CAR-T)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
California Institute for Regenerative Medicine ($8M grant for U.S. trial support)GMP manufacturing partner(s) in the United States for clinical supply production
04
Financials
- Market cap
- $690.9M
- Total revenue
- $0
- Enterprise value
- $459.8M
Beyond the preview
Go deeper on Nexcella.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nexcella.